NovaBay Pharmaceuticals CEO David Lazar to resign following stock transfer agreement
NegativeFinancial Markets

David Lazar, the CEO of NovaBay Pharmaceuticals, has announced his resignation following a stock transfer agreement. This development raises concerns about the company's leadership stability and future direction, especially as it navigates the complexities of the pharmaceutical industry. Investors and stakeholders will be closely watching how this change impacts NovaBay's operations and strategic goals.
— Curated by the World Pulse Now AI Editorial System